BRIC Countries (Brazil, Russia, India, China) Pharmaceuticals Market Summary, Competitive Analysis and Forecast, 2018-2027
Summary
The BRIC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $289.7 billion in 2022. China was the fastest growing country with a CAGR of 12.2% over the 2018-22 period.
Within the pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of $213.2 billion in 2022. This was followed by Russia, India and Brazil with a value of $31.9, $24.2, and $20.4 billion, respectively.
China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $355.2 billion in 2027, followed by Russia, India, Brazil with expected values of $40.0, $32.6 and $20.0 billion, respectively.
Scope
Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC pharmaceuticals market
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC pharmaceuticals market
Leading company profiles reveal details of key pharmaceuticals market players’ BRIC operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the BRIC pharmaceuticals market with five year forecasts
Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to Buy
What was the size of the BRIC pharmaceuticals market by value in 2022?
What will be the size of the BRIC pharmaceuticals market in 2027?
What factors are affecting the strength of competition in the BRIC pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitors in the BRIC pharmaceuticals market?